<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679666</url>
  </required_header>
  <id_info>
    <org_study_id>2008H0050,2008H0049</org_study_id>
    <nct_id>NCT00679666</nct_id>
  </id_info>
  <brief_title>Corneal Crosslinking in Keratoconus and Corneal Ectasia</brief_title>
  <acronym>CXL</acronym>
  <official_title>Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, single site to determine the safety and effectiveness of performing
      corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes progressive
      keratoconus or corneal ectasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After epithelial surface removal riboflavin drops are applied until there is saturation of
      the cornea.Then the UVA light is turned on to active the crosslinking process while drops are
      continued for the 30 minute of lamp use to replenish the riboflavin.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator no longer at university
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in keratometry</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>best spectacle-corrected visual acuity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Progressive Keratoconus</condition>
  <condition>Corneal Ectasia</condition>
  <arm_group>
    <arm_group_label>Sham treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects are randomized to control (sham) group or a treatment group with the control group crossed over to the treatment group at the 3 month visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After randomization, the active arm will have the collagen crosslinking intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Vitamin B2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.</description>
    <arm_group_label>Sham treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of keratoconus with documented progression over the previous 12 months.

          -  Diagnosis of corneal ectasia

          -  Must be able to complete all study visits.

        Exclusion Criteria:

          -  Prior corneal surgery in keratoconus group

          -  Corneal scarring

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Keates, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ohio State Univesity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSU Havener Eye Institute</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>May 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2008</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>keratoconus</keyword>
  <keyword>ectasia</keyword>
  <keyword>cross-linking</keyword>
  <keyword>riboflavin</keyword>
  <keyword>UVA light</keyword>
  <keyword>cornea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

